Predictive value of excision repair cross-complementing rodent repair deficiency complementation group 1 and ovarian cancer risk

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1799-1802

  He, Shan Yang ^a   Xu, Lin ^b   Niu, Gang ^a   Ke, Pei Qi ^a   Feng, Miao Miao ^a   Shen, Hong Wei ^a  

^a First Affiliated Hospital   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chinese population; ERCC1; Ovarian cancer; Polymorphism

Indexed keywords

DNA BINDING PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; XRCC1 PROTEIN;

ARTICLE; CASE CONTROL STUDY; CHINA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MIDDLE AGED; OVARY TUMOR; POLYMERASE CHAIN REACTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CHINA; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 84872683143     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1799     Document Type: Article

References (17)

1. Avraam K, Pavlakis K, Papadimitriou C, et al (2011). The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer. Eur J Gynaecol Oncol, 32, 516-20.
2. Bessho T, Sancar A, Thompson LH, et al (1997). Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Chem, 272, 3833-7.
3. Jin F, Shu XO, Devesa SS, et al (1993). Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972-89. Cancer Causes Control, 4, 355-60.
4. Krivak TC, Darcy KM, Tian C, et al (2008). Gynecologic Oncology Group Phase III Trial. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol, 26, 3598-606.
5. Lin F, Lin K, Xie X, et al (2010). Increased ERCC1 protein expression is associated with suboptimal debulking in advanced epithelial ovarian cancer. Anticancer Res, 30, 2447-52.
6. Li QQ, Yunmbam MK, Zhong X, et al (2001). Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cell Mol Biol (Noisy-le-grand), 47, OL61-72.
7. Liu Y, Scheurer ME, El-Zein R, et al (2009). Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev, 18, 204-14.
8. Matullo G, Guarrera S, Sacerdote C, et al (2005). Polymorphisms/ haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev, 14, 2569-78.
9. Moreno V, Gemignani F, Landi S, et al (2006). Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res, 12, 2101-8.
10. Rajaraman P, Hutchinson A, Wichner S, et al (2010). DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol, 12, 37-48.
11. Reed E, Yu JJ, Davies A, et al (2003). Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res, 9, 5299-305.
12. Ries LAG, Young JL, Keel GE, et al (2007). SEER Program, NIH Pub. No. 07-6215. National Cancer Institute; Bethesda, MD: 2007. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics.
13. van Duin M, de Wit J, Odijk H, et al (1986). Molecular characterization of the human excision repair gene ERCC- 1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell, 44, 913-23.
14. Weberpals J, Garbuio K, O'Brien A, et al (2009). The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer, 124, 806-15.
15. Wilson MD, Ruttan CC, Koop BF, et al (2001). ERCC1: a comparative genomic perspective. Environ Mol Mutagen, 38, 209-15.
16. Zhou W, Liu G, Park S, et al (2005). Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev, 14, 491-6.
17. Zienolddiny S, Campa D, Lind H, et al (2006). Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis, 27, 560-7.